Loading…
Regulatory clearance expands market reach for preeclampsia risk assessment.
Trinity Biotech plc (XNAS: TRIB) announced on August 14, 2025, that it has received regulatory approval from the New York State Department of Health to begin offering the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for preeclampsia risk assessment.
The approval allows Trinity Biotech to extend its market presence in New York, enhancing access to its preeclampsia screening solution. The company now has the green light to provide this critical test in one of the largest states in the U.S., potentially increasing its customer base and revenue streams.
With a free float of 325,114,000 shares, Trinity Biotech continues to leverage its regulatory successes to expand its footprint in the medical diagnostics sector.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.